ASH 2023 | Impact of prior bendamustine exposure on BsAb treatment outcomes in patients with B-cell lymphoma
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines a retrospective, multicenter study looking at the outcomes of patients with large B-cell lymphoma (LBCL) and follicular lymphoma (FL) who were previously exposed to bendamustine and subsequently treated with bispecific antibody (BsAb) treatment. The study included 143 patients and showed that exposure to bendamustine-containing regimens prior to BsAb therapy does not seem to confer a negative impact on survival or response rates. These findings differ from those which have been reported in the CAR T-cell setting. Further studies are needed to confirm these findings and to elucidate whether more recent bendamustine exposure also has no effect. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AstraZeneca, MSD, Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Janssen, Miltenyi, AbbVie
Consultancy: Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Autolus, Miltenyi
